Caprion

Accelerating precision medicine™

Press Release

Caprion Pharmaceuticals Announces Biomarker Discovery Collaboration with Berlex Biosciences

Montreal, Canada - January 24, 2006 - Caprion Pharmaceuticals Inc. today announced a research collaboration with Berlex Inc., a US affiliate of Schering AG Germany (NYSE: SHR, FSE: SCH). The collaboration will use Caprion's CellCarta® proteomics platform to support biomarker discovery. Caprion will identify pharmacodynamic biomarkers in plasma resulting from the administration of Berlex compounds in pre-clinical development.

"Caprion is looking forward to working with Berlex on their pre-clinical therapeutic candidates," noted Dr. Daniel Chelsky, Chief Scientific Officer at Caprion. "We believe Caprion's capabilities in the discovery of protein biomarkers will significantly impact our partner's development efforts."

Caprion's proprietary proteomics platform comprehensively profiles the expression and identity of proteins detected in tissues and blood plasma. Caprion is presently conducting biomarker discovery programs in other indications for several pharmaceutical and biotechnology companies.

###

About Caprion Pharmaceuticals Inc.
Caprion is a drug discovery and development company applying its proprietary proteomics technologies to develop innovative pharmaceutical products, initially in oncology and infectious disease. The Company's most advanced program will enter Phase II clinical trials in the US for Shiga-toxin producing E. coli infection (STEC) in the third quarter of 2006. Caprion's proteomics discovery platform - CellCarta® - has become a leading means for profiling proteins in blood and solid tumors. Caprion's strategy is to leverage platform discovery and development collaborations in two key areas - oncology and plasma profiling - to fund and further build its own pipeline of clinical programs. In addition to its leading program in STEC, Caprion has signed major research alliances in Colon, Prostate and Lung Cancer with Biogen Idec, AstraZeneca, ICOS Corporation, Abbott Laboratories and ImClone Systems, as well as numerous alliances for plasma profiling and novel biomarker discovery with leading pharmaceutical companies. For more on Caprion, please visit www.caprion.com.

FOR MORE INFORMATION CONTACT:

Caprion Pharmaceuticals
Nathalie Uson
Caprion Pharmaceuticals Inc.
(514) 940-3617

Back to news list


Caprion

Accreditations & Certifications

CAP accreditation and CLIA certification

CAP Accredited

Headquarters

+1 514.360.3600
+1 877.776.3443
141 President Kennedy Ave., Suite SB-5658
Montreal, Quebec
CANADA

USA

Primity Bio
48383 Fremont Blvd
Suite 118
Fremont, CA 94538
Tel.: +1 858.229.2529

Serametrix
2235 Farraday Ave,Suite N,
Carlsbad, CA, 92008, USA
Tel: +1 760 652 4060

HistoGeneX
1331 W 75th St #401,
Naperville, IL 60540, USA
Tel: +1 630-473-6655
info@histogenex.com

AUSTRALIA

Serametrix Party Limited
Suite 4/54-60 Briggs Street
Camperdown, NSW, 2050
Australia
+61 2 9168 5908

EUROPE

Caprion Biosciences Inc.
+32 (0) 71 96 23 36
8 rue Adrienne Bolland
6041 Gosselies
BELGIUM

Serametrix
Unit 22, Surrey Technology Centre,
40 Occam Road,
Guildford, Surrey, UK
GU2 7YG
Tel: +44 1483 685599

Antwerp, Belgium
HistoGeneX
Sint-Bavostraat 78
2610 Antwerpen (Wilrijk)
Belgium
Tel: +32 3 50 20 500
Sample Reception: +32 3 50 20 620
Shipments: +32 3 50 20 625

CANADA LAB

201 President Kennedy Ave., Suite PK-3900
Montreal, Quebec
CANADA
+1 514.360.3600
+1 877.776.3443



Follow us

        

Contact

+1 877.776.3443

info@caprion.com